Key facts
- Baymatob’s last known valuation is $5.4M (Mar 2024).
- It has raised $4.5M; the latest was Later Stage VC in Dec 2025.
- Notable investors include ANDHealth, Edale Capital, Albert Impact Ventures, Australian Unity, Brandon Biocatalyst — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Baymatob
- ·The full record, as it builds
Funding rounds
No funding rounds for Baymatob are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Baymatob
Developer of an AI-guided medical equipment designed to improve health outcomes for mothers and their babies. The company's product demonstrates the ability to identify women who are at higher risk of developing postpartum hemorrhage before they give birth and predicts clinical actions to prevent the leading cause of preventable maternal death, enabling healthcare providers to acquire, interpret, and predict critical information on pregnancy progression and risks to mothers and their babies.
- Sector
- Healthcare
- HQ
- Leichhardt, Australia
- Founded
- 2013
- Employees
- 20
- Website
- baymatob.com/
- Ownership
- Privately Held (backing)
Baymatob doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Baymatob shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Baymatob in its N-PORT filings yet. We sweep new filings monthly.